BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23064212)

  • 21. Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.
    Maier FC; Schmitt J; Maurer A; Ehrlichmann W; Reischl G; Nikolaou K; Handgretinger R; Pichler BJ; Thaiss WM
    Oncotarget; 2016 Oct; 7(41):67403-67411. PubMed ID: 27602580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
    Furman WL; McCarville B; Shulkin BL; Davidoff A; Krasin M; Hsu CW; Pan H; Wu J; Brennan R; Bishop MW; Helmig S; Stewart E; Navid F; Triplett B; Santana V; Santiago T; Hank JA; Gillies SD; Yu A; Sondel PM; Leung WH; Pappo A; Federico SM
    J Clin Oncol; 2022 Feb; 40(4):335-344. PubMed ID: 34871104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics.
    Yang CT; Kim YS; Wang J; Wang L; Shi J; Li ZB; Chen X; Fan M; Li JJ; Liu S
    Bioconjug Chem; 2008 Oct; 19(10):2008-22. PubMed ID: 18763821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
    Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
    J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
    Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A
    J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
    Cai H; Li Z; Huang CW; Shahinian AH; Wang H; Park R; Conti PS
    Bioconjug Chem; 2010 Aug; 21(8):1417-24. PubMed ID: 20666401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.
    Wei L; Butcher C; Miao Y; Gallazzi F; Quinn TP; Welch MJ; Lewis JS
    J Nucl Med; 2007 Jan; 48(1):64-72. PubMed ID: 17204700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
    Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
    Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.
    Zeglis BM; Sevak KK; Reiner T; Mohindra P; Carlin SD; Zanzonico P; Weissleder R; Lewis JS
    J Nucl Med; 2013 Aug; 54(8):1389-96. PubMed ID: 23708196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.
    Otto M; Barfield RC; Martin WJ; Iyengar R; Leung W; Leimig T; Chaleff S; Gillies SD; Handgretinger R
    Clin Cancer Res; 2005 Dec; 11(23):8486-91. PubMed ID: 16322312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hu14.18K.322A Causes Direct Cell Cytotoxicity and Synergizes with Induction Chemotherapy in High-Risk Neuroblastoma.
    Thomas M; Nguyen TH; Drnevich J; D'Souza AM; de Alarcon PA; Gnanamony M
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
    Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
    Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.
    Furman WL; Federico SM; McCarville MB; Shulkin BL; Davidoff AM; Krasin MJ; Sahr N; Sykes A; Wu J; Brennan RC; Bishop MW; Helmig S; Stewart E; Navid F; Triplett B; Santana VM; Bahrami A; Anthony G; Yu AL; Hank J; Gillies SD; Sondel PM; Leung WH; Pappo AS
    Clin Cancer Res; 2019 Nov; 25(21):6320-6328. PubMed ID: 31601569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
    Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
    Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
    Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
    Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
    J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
    Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
    Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.